ArticlePloS one2011
Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Advances in protein dot blot: principles, technical specifics, applications, and future perspectives.Frontiers in molecular biosciences · 2026Review
- Decreased circulating transforming growth factor-beta (TGF-β) and kidney TGF-β immunoreactivity predict renal disease in cats with naturally occurring chronic kidney disease.Journal of feline medicine and surgery · 2023Article
- Article
- Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis.Nature communications · 2022Article
- Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- High TRIAP1 expression in penile carcinoma is associated with high risk of recurrence and poor survival.Annals of translational medicine · 2019Article
- Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma.Oncology letters · 2019Article
- Frequency of I655V SNP of HER-2/3 Biotech · 2019Article
- High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.Oncotarget · 2016Article
- Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.Angewandte Chemie (International ed. in English) · 2015Article
- Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling.British journal of cancer · 2014Article
- Molecular markers for breast cancer: prediction on tumor behavior.Disease markers · 2014Review
- Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Expert opinion on therapeutic targetsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) is one of the most important prognostic and predictive factors for breast cancer patients. Recently, serum HER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay (ELISA) has been shown to predict tumor HER2 status and reveal its association with tumor progression, recurrence and poor prognosis. In this study, we established a new method, dot blot assay, to measure the serum HER2 level in breast cancer patients and further to evaluate the clinical value for monitoring breast cancer progression. We found that the serum HER2 level measured by dot blot assay was significantly correlated with tissue HER2 status in breast cancer patients (P = 0.001), and also significantly correlated with HER2 level measured by ELISA (P = 1.06×10(-11)). Compared with ELISA method, the specificity and sensitivity of dot blot assay were 95.3% and 65.0%, respectively. The serum HER2 levels of patients with grade III or ER-negative were higher than those with grade I-II (P = 0.004) and ER-positive (P = 0.033), respectively. Therefore, the novel dot blot method to detect serum HER2 level is a valid and inexpensive assay with potential application in monitoring breast cancer progression in clinical situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.